Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic VEX in Advanced Breast Cancer
NCT04304352Phase 2Unknown
- Sponsor
- European Institute of Oncology
- Start
- Jul 2011
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, capecitabine, vinorelbine in breast cancer, sponsored by European Institute of Oncology. Status: unknown.
02
Drugs
cyclophosphamidecapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04304352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304352.